The ASSIST CLAD study: A phase 2 randomized controlled trial of mesenchymal stromal cells for new-onset chronic lung allograft dysfunction
Abstract
Background: Chronic lung allograft dysfunction (CLAD) remains the primary limitation to long-term survival after lung transplantation. We conducted a multicenter, phase 2, double-blind, randomized controlled trial of intravenous (IV) allogenic bone marrow-derived mesenchymal stromal cells (MSC) in lung transplant recipients with new-onset CLAD.
Methods: Participants (bilateral or single lung transplant, aged ≥18 years, >6 months post-transplant and with a persistent fall in forced expiratory volume in 1 second [FEV1] and/or forced vital capacity [FVC] >20% from best post-transplant values within 12 months) were randomized (1:1, target n = 41 per arm) to receive MSC (2 × 10⁶ cells/kg IV twice weekly for 2 weeks) or placebo. The primary end-point was progression-free survival at 12 months, defined as a composite of all-cause mortality and freedom from CLAD progression (fall in FEV1 decline >10%).
Results: Fifty-nine participants were randomized. Fifty-eight received treatment (31 placebo; 27 MSC). MSC treatment did not improve progression-free survival: Seventeen of 31 (55%) in the placebo arm vs 11 of 27 (41%) in the MSC arm (relative risk 0.74 (0.42-1.29), p = 0.30). Lung function decline was similar between groups. The FEV1 slope (95% CI) declined by 6.43 (-11.78, -1.08) ml/week in the MSC group and 9.14 (-14.29, -3.99) ml/week in the placebo group (difference: 2.56 (-4.88, 9.99) ml/week, p = 0.50). FVC declined by 4.58 (-7.51, -1.65) ml/week in the MSC group and by 4.19…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 41 participants or records.
Read the paper
Related studies
- eggNOG 5.0: a hierarchical, functionally and phylogenetically annotated orthology resource based on 5090 organisms and 2502 viruses
- Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer
- OptiType: precision HLA typing from next-generation sequencing data
- Nicotinic Cholinergic System and COVID-19: In Silico Identification of an Interaction between SARS-CoV-2 and Nicotinic Receptors with Potential Therapeutic Targeting Implications
- Saccharomyces cerevisiae cells have three Omega class glutathione S-transferases acting as 1-Cys thiol transferases
- Hemolysis at low blood flow rates: in-vitro and in-silico evaluation of a centrifugal blood pump
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.